Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...
Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...
Abstract: Reconfigurable arrays enable flexible utilization of system resources and thus become a key technology in modern radar and communication systems. Once the array is reconfigured, its steering ...
Neutral-atom arrays are a rapidly emerging platform to create quantum computers. In a foundational study led by graduate students Aaron Holman and Yuan Xu from the Will and Yu labs, respectively, the ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...
In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...
Selling the stake in REV102 frees RallyBio up to focus on the C5 inhibitor RLYB116. (NWM/iStock/Getty Images Plus) Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 ...
Method references are a shorthand way to write lambda expressions that call a single method. Rather than implementing a method in a functional interface, a method reference simply points to an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results